Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth

Area of Science:

• Oncology
• Cell Biology
• Genetics

Background:

• Breast cancer brain metastases (BCBM) are a significant cause of mortality with poorly understood adaptation mechanisms.
• BCBM development involves a latency period and adaptation to the unique brain microenvironment.

Purpose of the Study:

• To elucidate the molecular mechanisms driving breast cancer cell adaptation and survival within the brain microenvironment.
• To identify novel therapeutic targets for preventing or treating BCBM.

Main Methods:

• Combined time-course RNA-sequencing of BCBM development with a Drosophila melanogaster genetic screen.
• Utilized proteomic analysis to identify proteins regulated by key mediators.
• Investigated the role of specific proteins in cell-extracellular matrix interactions and signaling pathways.

Main Results:

• Identified Rab11b as a critical mediator of metastatic adaptation in breast cancer to the brain.
• Rab11b controls the cell surface proteome via protein recycling, notably integrin β1.
• Rab11b-mediated integrin β1 expression facilitates brain extracellular matrix engagement and mechanotransduction signaling, promoting cancer cell survival.
• Lipophilic statins were shown to inhibit Rab11b activity, preventing breast cancer adaptation to the brain microenvironment.

Conclusions:

• Rab11b-mediated recycling of integrin β1 is a key regulator of breast cancer brain metastasis.
• The 'recycleome'—recycling-based control of the cell surface proteome—is a novel driver of metastatic adaptation and outgrowth.
• Lipophilic statins show potential as a therapeutic strategy against BCBM by targeting Rab11b-dependent pathways.